Advertisement

Picture Swiss Biotech Association LSE Swiss Biotech Days 2025 Basel 650x100px
Organisation › Details

PsiOxus Therapeutics Ltd.

PsiOxus Therapeutics is an Oxford, UK-based development stage biotechnology company with a particular focus in immune therapeutics in oncology. PsiOxus has developed a patented platform for tumour-targeted delivery based on its oncolytic vaccine, enadenotucirev. Enadenotucirev’s unique design allows it to be delivered systemically via intravenous administration. The anti-cancer scope of enadenotucirev can be expanded through “arming” – a process that involves addition of new genes into enadenotucirev. The "Armed EnAd" platform makes possible creation of a broad range of unique oncolytic immune therapeutics, including oncolytic vaccines that express one or more antibodies (AbEnAd), cytokines or other immunomodulatory proteins, or nucleotide based payloads such as RNAi. The Armed EnAd platform is in preclinical stage, while phase I/II clinical trials are ongoing with the parent unarmed EnAd in different tumour types. *

 

Period Start 2010-12-15 merged
Period End 2023-01-05 renamed
  Group Akamis Bio (Group)
  Today Akamis Bio Ltd.
  Predecessor Myotec Therapeutics Ltd.
  Successor Akamis Bio Ltd.
Product Industry oncolytic virus (cancer-cilling virus, virotherapy for cancer, virus-based cancer therapy)
Persons Person Davis, Howard E. (PsiOxus 202208– CEO based in Boston area before Atlas Venture + Third Harmonic Bio + Flagship)
  Person 2 Paoletti, Paolo (GammaDelta Therapeutics 201705– CEO before Kesios Therapeutics CEO + GSK)
     
Region Region Abingdon, Oxfordshire
  Country United Kingdom (GB)
  Street 154B Brook Drive
Milton Park
  City OX14 4SD Abingdon, Oxfordshire
  Tel +44-1235-835328
    Address record changed: 2020-12-02
     
Basic data Employees n. a.
     
    * Document for »About Section«: 
     
   
Record changed: 2023-07-10

Advertisement

Picture Swiss Biotech Association LSE Swiss Biotech Days 2025 Basel 650x200px

More documents for Akamis Bio (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Berlin Partner Events RegMed Forum 2025 HealthCapital 650x300px




» top